- Home
- MIRM vs MNTSW Comparison
MIRM vs MNTSW Comparison
Compare MIRM & MNTSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MNTSW
- Stock Information
- Founded
- MIRM 2018
- MNTSW N/A
- Country
- MIRM United States
- MNTSW United States
- Employees
- MIRM N/A
- MNTSW 123
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MNTSW Military/Government/Technical
- Sector
- MIRM Health Care
- MNTSW Industrials
- Exchange
- MIRM Nasdaq
- MNTSW Nasdaq
- Market Cap
- MIRM 1.9B
- MNTSW N/A
- IPO Year
- MIRM 2019
- MNTSW 2019
- Fundamental
- Price
- MIRM $40.00
- MNTSW $0.02
- Analyst Decision
- MIRM Strong Buy
- MNTSW
- Analyst Count
- MIRM 11
- MNTSW 0
- Target Price
- MIRM $58.55
- MNTSW N/A
- AVG Volume (30 Days)
- MIRM 447.2K
- MNTSW N/A
- Earning Date
- MIRM 05-07-2025
- MNTSW N/A
- Dividend Yield
- MIRM N/A
- MNTSW N/A
- EPS Growth
- MIRM N/A
- MNTSW N/A
- EPS
- MIRM N/A
- MNTSW N/A
- Revenue
- MIRM $336,888,000.00
- MNTSW N/A
- Revenue This Year
- MIRM $29.51
- MNTSW N/A
- Revenue Next Year
- MIRM $20.27
- MNTSW N/A
- P/E Ratio
- MIRM N/A
- MNTSW N/A
- Revenue Growth
- MIRM 80.76
- MNTSW N/A
- 52 Week Low
- MIRM $23.14
- MNTSW N/A
- 52 Week High
- MIRM $54.23
- MNTSW N/A
- Technical
- Relative Strength Index (RSI)
- MIRM 41.05
- MNTSW N/A
- Support Level
- MIRM $38.22
- MNTSW N/A
- Resistance Level
- MIRM $40.14
- MNTSW N/A
- Average True Range (ATR)
- MIRM 2.24
- MNTSW 0.00
- MACD
- MIRM 0.07
- MNTSW 0.00
- Stochastic Oscillator
- MIRM 48.50
- MNTSW 0.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MNTSW Momentus Inc. Warrant
Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.